SARS-CoV-2 vaccination in heart transplantation: What we do and do not know

Saima Aslam; Michael G. Ison

doi:10.1016/j.healun.2021.10.017

SARS-CoV-2 vaccination in heart transplantation: What we do and do not know

Saima Aslam, Michael G. Ison^*

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › peer-review

7 Scopus citations

Original language	English (US)
Pages (from-to)	158-160
Number of pages	3
Journal	Journal of Heart and Lung Transplantation
Volume	41
Issue number	2
DOIs	https://doi.org/10.1016/j.healun.2021.10.017
State	Published - Feb 2022

Funding

Michael G Ison reports research support, paid to Northwestern University, from AiCuris, GlaxoSmithKline, Janssen and Shire; he is a paid consultant for Adagio, AlloVir, Celltrion, Cidara, Genentech, Roche, Janssen, Shionogi, Viracor Eurofins; he is also a paid member of DSMBs from Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda and Vitaeris. Saima Aslam reports grant funding from the Cystic Fibrosis Foundation; she is also a consultant for Merck (honoraria received), Gilead (honoraria received), and BioMx (unpaid). Michael G Ison received research support from NCATS UL1TR001422.

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Transplantation
Pulmonary and Respiratory Medicine
Surgery

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.healun.2021.10.017

Cite this

@article{f083993119984633a1ad380afc5da792,

title = "SARS-CoV-2 vaccination in heart transplantation: What we do and do not know",

author = "Saima Aslam and Ison, {Michael G.}",

note = "Funding Information: Michael G Ison reports research support, paid to Northwestern University, from AiCuris, GlaxoSmithKline, Janssen and Shire; he is a paid consultant for Adagio, AlloVir, Celltrion, Cidara, Genentech, Roche, Janssen, Shionogi, Viracor Eurofins; he is also a paid member of DSMBs from Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda and Vitaeris. Saima Aslam reports grant funding from the Cystic Fibrosis Foundation; she is also a consultant for Merck (honoraria received), Gilead (honoraria received), and BioMx (unpaid). Funding Information: Michael G Ison received research support from NCATS UL1TR001422. ",

year = "2022",

month = feb,

doi = "10.1016/j.healun.2021.10.017",

language = "English (US)",

volume = "41",

pages = "158--160",

journal = "Journal of Heart and Lung Transplantation",

issn = "1053-2498",

publisher = "Elsevier USA",

number = "2",

}

TY - JOUR

T1 - SARS-CoV-2 vaccination in heart transplantation

T2 - What we do and do not know

AU - Aslam, Saima

AU - Ison, Michael G.

N1 - Funding Information: Michael G Ison reports research support, paid to Northwestern University, from AiCuris, GlaxoSmithKline, Janssen and Shire; he is a paid consultant for Adagio, AlloVir, Celltrion, Cidara, Genentech, Roche, Janssen, Shionogi, Viracor Eurofins; he is also a paid member of DSMBs from Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda and Vitaeris. Saima Aslam reports grant funding from the Cystic Fibrosis Foundation; she is also a consultant for Merck (honoraria received), Gilead (honoraria received), and BioMx (unpaid). Funding Information: Michael G Ison received research support from NCATS UL1TR001422.

PY - 2022/2

Y1 - 2022/2

UR - http://www.scopus.com/inward/record.url?scp=85120651454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85120651454&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2021.10.017

DO - 10.1016/j.healun.2021.10.017

M3 - Editorial

C2 - 34876356

AN - SCOPUS:85120651454

SN - 1053-2498

VL - 41

SP - 158

EP - 160

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

IS - 2

ER -

SARS-CoV-2 vaccination in heart transplantation: What we do and do not know

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this